Indaptus Therapeutics Inc (INDP) FinancialsINDPIndaptus Therapeutics Inc

Evaluating the bottom line, Indaptus Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -318.04%, provide a clear picture of how effectively INDP converts its operational activities into shareholder value.

In the context of the broader market, INDP competes directly with industry leaders such as AQST and CTMX. With a market capitalization of $421.05M, it holds a significant position in the sector. When comparing efficiency, INDP's gross margin of N/A stands against AQST's 70.93% and CTMX's 100.00%. Such benchmarking helps identify whether Indaptus Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has shown a volatile financial performance with net income losses ranging from -4131047.00 USD to -8112450.00 USD over the past quarters. The current ratio is strong at 19.48 for Q2 2026, indicating good short-term liquidity.